Navigation Links
BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
Date:1/30/2008

NOVATO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 19th Annual Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference in New York City on Wednesday, February 6, 2008 at 1:40 p.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R) and Naglazyme(R) are registered
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Cambridge Semantics , ... by Semantic Web technology, and Informa , ... services for the academic and scientific, professional and ... solution ‘Smart Data Lake for Clinical Trial and ... 2015 Bio-IT ‘Best of Show’ Award. , ...
(Date:4/16/2015)... April 16, 2015 Regis Technologies looks ... Association for Cancer Research (AACR) annual meeting. Regis will ... Center, starting Saturday, April 18, in Philadelphia and running ... to title of the oldest and largest organization focused ... and grants, and partners with survivors to promote awareness ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ... Securities Exchange: PBT.U), is pleased to announce that the ... on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon , ... an update on the key programs at its subsidiaries, ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... Other important parameters for optimizing electroporation., , , , , , , ... , Pulse length , , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , Influence ...
... , , , , ... , to degradation than DNA. Unlike Deoxyribonucleases (DNases), ... can therefore easily be inactivated with chelating , ... requirements and advantage of the 2 hydroxyl groups adjacent to ...
... How can Brinkmann TM Help ? , , , , , ... , , ... laboratory technique that is performed everyday, for a good portion , ... Due to the nature of the tests being conducted, only short breaks , ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Decontamination and inhibition of ribonucleases 2Decontamination and inhibition of ribonucleases 3Decontamination and inhibition of ribonucleases 4Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 2Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 3Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 4
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... are significantly more open to the idea of "designing" babies ... psychologists at the University of East Anglia. , The findings ... Festival of Science on Setpember 5. , Dr. Hampton and ... Studies examined what different groups of people in the UK ...
... that influences several aspects of nicotine-induced behaviors in the ... Drug Abuse, was presented today at the American College ... PhD, associate professor of psychiatry and her colleagues at ... a molecule called CREB in a brain area called ...
... In a finding that broadens our understanding of ... risk when crossing roads and draw on an ... primates--of protective "socio-spatial" organization that produces flexible, adaptive, ... facing risk. The research is reported by Kimberley ...
Cached Biology News:Designer babies - what would you do for a 'healthy' baby? 2New research identifies gene important for nicotine's effects on the brain 2Road-crossing in chimpanzees: A risky business 2
Performance, mycoplasma, virus, and endotoxin tested...
... Gel Loading Buffer is ... and tracking of DNA ... native polyacrylamide gels. This ... density sucrose which allows ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
ready-to-use solution...
Biology Products: